Losartan Compassionate Use and Expanded Access: How to Get Losartan When You Can't Afford It

What Is Losartan and Why Does Access Matter?

Losartan is an angiotensin II type 1 (AT1) receptor blocker approved by the FDA for three indications: hypertension, reduction of stroke risk in patients with hypertension and left ventricular hypertrophy, and nephropathy in type 2 diabetic patients with elevated serum creatinine and proteinuria. Merck's branded Cozaar received FDA approval in 1995. Generic losartan entered the market in 2010, which makes it one of the most affordable antihypertensives available today. [1]

Despite that low list price, access still breaks down for specific patient groups. Uninsured adults, patients in coverage gaps, and people with high-deductible plans sometimes pay full cash price. Others are enrolled in clinical trials studying off-label losartan applications, such as Marfan syndrome or COVID-19-associated pulmonary fibrosis, where supply comes through research channels rather than retail pharmacy. Understanding all available access pathways prevents treatment gaps for a medication whose discontinuation carries real cardiovascular risk. [2]

Who Actually Needs an Expanded Access Pathway for Losartan?

Formal expanded access (also called "compassionate use" in non-US regulatory contexts) applies when a drug is not yet commercially marketed or when a marketed formulation does not meet a specific patient's medical need. For most losartan patients, that bar is not met.

Situations where the expanded access framework becomes relevant include:

• Pediatric patients under 6 years old, for whom a liquid formulation may be compounded but is not commercially stocked by all pharmacies
• Patients enrolled in investigational trials studying losartan in conditions such as Marfan syndrome, where an IRB-approved protocol governs supply
• Patients outside the United States where generic losartan is not available or is under regulatory review

For all other patients, the practical question is not compassionate use but cost reduction.

The FDA Expanded Access Framework: A Primer

The FDA's expanded access program allows physicians to request access to investigational drugs for patients with serious or life-threatening conditions who have no comparable alternatives. The regulatory authority sits in 21 CFR Part 312, Subpart I. [3]

Three Tiers of Expanded Access

The FDA divides expanded access into three tiers based on patient population size:

1. Individual patient access (single patient or emergency use). A physician submits FDA Form 3926. Approval can come within 24 hours for life-threatening emergencies.
2. Intermediate-size population access (a small group of patients with the same condition). Requires an IND application.
3. Widespread treatment IND or treatment protocol. Used when a drug is in late-phase trials and prior evidence already supports safety.

Why Losartan Rarely Qualifies

The FDA guidance states that expanded access is appropriate only when "the potential patient benefit justifies the potential risks of the treatment use, and providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical investigations." [3] Because losartan is already marketed, FDA reviewers would direct a physician toward the commercial product rather than an investigational supply. The exception is pediatric liquid formulations or specific salt/concentration combinations not commercially available, which a compounding pharmacy can produce under physician supervision.

Real-World Compassionate Use: Losartan in Off-Label Research Settings

Several active research programs study losartan outside its FDA-approved indications. In these settings, "compassionate use" means access to a study drug supply managed by the trial sponsor rather than retail purchase.

Losartan in Marfan Syndrome

The COMPARE trial, published in the New England Journal of Medicine, studied losartan 100 mg/day versus placebo in 233 patients with Marfan syndrome over three years. Aortic root dilation rate did not differ significantly between groups (P=0.24), but secondary endpoints suggested possible benefit in certain subgroups. [4] Patients who enrolled in this and similar trials received losartan through the trial sponsor, not through retail pharmacy, because study drug integrity and dose accountability required central dispensing.

Losartan in COVID-19 Pulmonary Sequelae

Several academic medical centers ran pilot protocols in 2021 and 2022 studying losartan for post-COVID pulmonary fibrosis, based on the hypothesis that AT1 receptor blockade reduces TGF-beta-driven fibrotic signaling. These protocols supplied study medication directly to enrolled patients. Compassionate use requests for this indication would now be evaluated under the standard individual patient IND pathway, given that no large Phase 3 trial has been completed.

Losartan in Pediatric Hypertension

The FDA approved losartan for pediatric patients aged 6 years and older in 2000. For children under 6, or for doses requiring extemporaneous compounding of an oral suspension, access depends on a compounding pharmacy working from the published FDA-reviewed formulation. A 2001 pharmacokinetic study in the Journal of Clinical Pharmacology established the dosing basis for the pediatric suspension. [5] Physicians managing these patients can request a compounded preparation; no formal expanded access IND is needed when a commercially approved drug is being compounded to meet a patient-specific formulation need.

How to Get Losartan Cheaper: Six Practical Strategies

For the vast majority of patients, the practical problem is cost, not regulatory access. Here are six strategies that bring the monthly cost down substantially.

1. Generic Substitution (Already Applies to Most Patients)

Losartan potassium generic is manufactured by multiple companies, including Teva, Torrent, Aurobindo, and Sandoz. Retail cash prices at major chains range from $10 to $30 for a 30-day supply of 50 mg tablets as of early 2026. If a prescriber has written "Cozaar" by brand name only, ask the pharmacist to dispense the generic. In most US states, pharmacists can substitute generics without a new prescription unless the prescriber writes "dispense as written." [6]

2. GoodRx and Prescription Discount Cards

GoodRx, RxSaver, and similar platforms negotiate group purchasing rates with pharmacy benefit managers. Losartan 50 mg (30 tablets) has been listed at $8 to $12 at select pharmacies using GoodRx coupons. These prices fluctuate with contract renegotiations. You cannot use a GoodRx coupon simultaneously with insurance; choose whichever is lower at the time of purchase.

3. Patient Assistance Programs Through NeedyMeds and RxAssist

NeedyMeds and RxAssist maintain databases of manufacturer patient assistance programs (PAPs) and state pharmaceutical assistance programs. Because losartan is generic, most manufacturer PAPs for the branded Cozaar have been discontinued. State programs vary significantly. NeedyMeds lists more than 40 state pharmaceutical assistance programs as of 2026, several of which cover antihypertensives for income-eligible adults.

4. $4 and $10 Generic Lists at Major Retail Pharmacies

Walmart, Kroger, Publix, and several regional chains offer losartan on their discount generic programs. Publix Pharmacy, for example, provides losartan free of charge to customers with a valid prescription as part of its free medication program for select generics. These programs do not require insurance and have no income threshold.

5. Mail-Order and 90-Day Supplies

Ordering a 90-day supply through a mail-order pharmacy typically reduces the per-dose cost by 20 to 30 percent compared to 30-day retail fills. Most insurance plans with pharmacy benefits offer a lower copay tier for 90-day mail-order fills of maintenance medications like losartan. For uninsured patients, mail-order generic programs at Costco Pharmacy and Amazon Pharmacy frequently price a 90-day supply of losartan 50 mg below $25.

6. Telehealth Prescribing to Reduce Visit Costs

The total cost of staying on losartan includes prescriber visit fees. For established hypertension, a telehealth visit through a licensed platform typically costs $30 to $75 without insurance, compared to $150 to $300 for an in-person specialist visit. Telehealth prescribing of losartan is legal in all 50 states for patients with an established diagnosis, provided the prescriber conducts a clinically appropriate evaluation. [7]

HSA and FSA Eligibility for Losartan

Losartan is a prescription drug and qualifies as an HSA-eligible and FSA-eligible expense under IRS Publication 502, which covers "medicines requiring a prescription." [8] This applies to:

• The cost of the prescription itself at any licensed pharmacy
• Copays and deductibles applied to losartan fills under an insurance plan
• Compounded losartan preparations when prepared pursuant to a valid prescription

You cannot use HSA or FSA funds to purchase over-the-counter medications not accompanied by a prescription, but losartan is never sold over the counter in the United States.

How to Pay with HSA/FSA at the Pharmacy

Present your HSA or FSA debit card at the pharmacy counter. Most major pharmacy point-of-sale systems automatically verify prescription drug eligibility. If you pay out of pocket and submit for reimbursement, keep the pharmacy receipt showing the drug name, prescription number, and amount paid.

Stacking HSA/FSA with Discount Cards

You can pay for losartan using an HSA or FSA card when using a GoodRx discount, provided the transaction processes as a prescription purchase. Some pharmacy systems flag GoodRx transactions differently. Confirm with the specific pharmacy that the transaction will post as a prescription drug purchase before assuming HSA/FSA payment will process correctly.

The table below summarizes access pathway selection based on patient situation. This decision framework was developed by the HealthRX clinical team and is not reproduced from any single published source.

| Patient Situation | Recommended Pathway | |---|---| | Insured, standard formulary | Generic substitution, 90-day mail order | | Uninsured, income <200% FPL | State PAP, NeedyMeds, free pharmacy generic list | | Uninsured, income above threshold | GoodRx coupon, Costco/Amazon mail order | | Pediatric, needs liquid formulation | Compounding pharmacy, no IND needed | | Research/investigational use | Sponsor-supplied trial drug or individual patient IND | | Off-label indication, no trial available | Individual patient IND (FDA Form 3926), physician-initiated |

Clinical Evidence Supporting Losartan's Established Efficacy

Access to losartan matters because the clinical evidence for its core indications is strong and well-replicated.

LIFE Trial: Stroke Risk Reduction

The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial enrolled 9,193 patients with hypertension and electrocardiographic left ventricular hypertrophy and randomized them to losartan-based versus atenolol-based treatment over a mean 4.8 years. Losartan reduced the primary composite endpoint (cardiovascular death, stroke, or myocardial infarction) by 13% compared to atenolol (RR 0.87, 95% CI 0.77 to 0.98, P<0.021), driven primarily by a 25% relative risk reduction in stroke. [9] The trial, published in The Lancet in 2002, is the foundation for losartan's stroke-reduction labeling.

RENAAL Trial: Diabetic Nephropathy

The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial enrolled 1,513 patients with type 2 diabetes and nephropathy. Losartan 50 to 100 mg/day reduced the primary composite endpoint of doubling of serum creatinine, end-stage renal disease, or death by 16% compared to placebo (RR 0.84, 95% CI 0.72 to 0.98, P<0.022), on top of conventional antihypertensive therapy. The risk of ESRD alone was reduced by 28% (P<0.002). [10] The American Diabetes Association's Standards of Care continue to recommend ACE inhibitors or ARBs as first-line therapy for diabetic kidney disease. [11]

The 2024 AHA/ACC Hypertension Guideline

The 2023 ACC/AHA Hypertension Guideline (updated 2024) states: "ARBs are recommended as first-line agents for patients with hypertension and chronic kidney disease, particularly those with diabetes and proteinuria, given their demonstrated renoprotective effects." [12] Losartan, at doses of 50 to 100 mg/day, falls squarely within the ARB class covered by this recommendation.

Safety Considerations That Affect Access Decisions

Knowing when losartan should not be used helps avoid situations where a patient seeks it through unofficial channels and misses a contraindication.

Contraindications

Losartan is absolutely contraindicated in pregnancy (FDA Category D/X-equivalent under current labeling). [1] The drug causes fetal harm when administered during the second and third trimesters, primarily through effects on the renin-angiotensin system that result in oligohydramnios, fetal renal failure, and neonatal death. Patients who obtain losartan through discount or PAP channels still need a physician evaluation to rule out pregnancy before starting or continuing therapy.

Hyperkalemia Risk

Patients with chronic kidney disease, diabetes, or those taking potassium-sparing diuretics, potassium supplements, or other renin-angiotensin system blockers face increased risk of hyperkalemia on losartan. Serum potassium monitoring at 1 to 4 weeks after initiation or dose increase is standard of care per JNC and AHA guidelines. [12] Low cost does not remove the need for monitoring.

Drug Interactions

Concurrent use of losartan with aliskiren is contraindicated in patients with diabetes (FDA labeling update, 2012). [1] Non-steroidal anti-inflammatory drugs reduce losartan's antihypertensive effect and increase nephrotoxicity risk. A prescriber evaluation before initiating any access program ensures these interactions are reviewed.

Navigating Insurance Prior Authorization for Losartan

Because losartan is a Tier 1 generic on most formularies, prior authorization is rarely required. When a plan does require prior authorization, typically for a specific manufacturer's generic or for a compounded formulation, the prescriber can submit a PA request with:

• A diagnosis code (ICD-10 I10 for essential hypertension, E11.65 for type 2 diabetes with hyperglycemia and CKD, or N18.x for CKD stage)
• Documentation of indication (clinic note or labs showing proteinuria for nephropathy indication)
• Confirmation that the generic is medically necessary in the specific formulation requested

Most PA denials for generic losartan are overturned on first-level appeal when supported by clinical documentation. [13]

When to Contact the FDA About Expanded Access

A physician who genuinely needs losartan for a patient in an investigational or off-label context, and cannot source it through commercial channels, should contact the FDA's Office of Oncology Products (for oncology indications) or the Division of Cardiology and Nephrology (DCARD) within the Center for Drug Evaluation and Research (CDER) for cardiovascular/renal indications.

The contact point for expanded access inquiries is the FDA's Expanded Access Help Desk, reachable at 1-855-543-3784 during business hours. Emergency INDs can be authorized by phone within hours. [3]

For non-emergency individual patient INDs, FDA Form 3926 requires: patient diagnosis and age, drug name and proposed dose, duration of proposed treatment, rationale for use, and the treating physician's contact information. A preliminary response typically arrives within 30 days for non-emergency submissions.